Vaxxas is a groundbreaking brand that is revolutionizing the world of vaccines through its innovative needle-free technology. By commercializing novel technology, Vaxxas aims to enhance the performance of existing and next-generation vaccines, completely reimagining what is possible in the field. Their approach, which has been validated in human clinical studies, significantly improves the efficiency and effectiveness of a vaccine's immune response.

One of the key advantages of Vaxxas' technology is its proprietary dry-coating technology. This technology eliminates or greatly reduces the need for vaccine refrigeration during storage and transportation, easing the burden of maintaining the vaccine cold chain. By targeting initial applications in infectious disease and oncology, Vaxxas aims to address critical healthcare challenges.

Vaxxas has formed collaborations with prestigious organizations such as Merck/MSD, the United States Biomedical Advanced Research and Development Authority (BARDA), the World Health Organization (WHO), and the Bill and Melinda Gates Foundation. Their dedicated management team and board of directors bring together experienced professionals from diverse backgrounds, ensuring that Vaxxas remains at the forefront of vaccine technology. With its groundbreaking technology, Vaxxas is poised to revolutionize the field of vaccines and make a significant impact on global healthcare